Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 290 results for breast cancer

  1. Cancer: breast cancer mortality rate (IND4)

    This indicator covers breast cancer mortality rates (female). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG04

  2. Cancer: breast screening (53 to 70 years) (IND65)

    This indicator covers the proportion of women aged 53 to 70 years whose record shows a breast screening test has been performed within the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG84

  3. Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

    Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.

  4. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.

  5. NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer

    Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.

  6. Draft guidance for the potential of new targeted treatment for type of advanced breast cancer

    NICE has today (26 September 2023) published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for treating advanced HER2-low breast cancer in adults.

  7. NICE publishes final draft guidance on Enhertu after commercial discussions conclude

    NICE does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.

  8. Change in treatment for people with early breast cancer to benefit around 4,000

    Around 4,000 people are set to benefit from a change in treatment for early breast cancer following provisional approval by NICE of abemaciclib in combination with hormone therapy.

  9. NICE recommends 2 new breast cancer drugs

    NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.

  10. New tests could spare people with early breast cancer from unnecessary chemotherapy

    More people with early breast cancer could be spared chemotherapy and therefore avoid the side effects associated with the treatment after tumour profiling tests were recommended by NICE.

  11. Developing NICE guidelines: the manual (PMG20)

    This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE

  12. Image-guided percutaneous laser ablation for primary and secondary liver tumours (IPG788)

    Evidence-based recommendations on image-guided percutaneous laser ablation for primary and secondary liver tumours. This involves heating up liver tissue to destroy tumours.

  13. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG58)

    Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer

  14. Past appeals and decisions

    for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945] 3 September 2020 TBC Afamelanotide for treating...

  15. Board, executive team and senior leaders interests register

    specialty adviser for medical oncology.Trustee 'It's in the Bag' testicular cancer charity.Member of Sciensus medical advisory...